Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954406 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02954406 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT02954406, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Gemcitabine
- DRUG Bendamustine
- DRUG TAK-659
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-03-05 |
| Est. Completion | 2020-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954406
The ClinicalTrials.gov registry entry for NCT02954406 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT02954406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954406 about?
NCT02954406 is a clinical study titled "A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma". The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.
What is the current status of trial NCT02954406?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2017-03-05. Estimated completion is 2020-07-27.
What interventions are being tested in trial NCT02954406?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Gemcitabine (DRUG), Bendamustine (DRUG), TAK-659 (DRUG).
Who is sponsoring clinical trial NCT02954406?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.